Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 32Carcinoma, Intraductal, Noninfiltrating 5Breast Carcinoma In Situ 4Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Infertility 2Breast Neoplasms, Male 2Breast Diseases 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Pancreatic Cyst 1Neoplasms by Site 1Hypogonadism 1Hot Flashes 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ductal 1Anovulation 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

testosterone undecanoate 1testosterone 17 beta-cypionate 1Testosterone Propionate 1Testosterone 1Tamoxifen 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1Methyltestosterone 1Mental Status and Dementia Tests 1Gels 1Drug Evaluation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypogonadism × Tamoxifen × 90 days × Clear all
NCT07535905 2026-04-17

REVIVE

University Health Network, Toronto

Phase 2 Not yet recruiting
96 enrolled
Genitourinary

Hypogonadism, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡